NCT06104423View on ClinicalTrials.gov

Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients

PHASE4CompletedINTERVENTIONAL
Enrollment

266

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

February 19, 2024

Study Completion Date

February 19, 2024

Conditions
Hypertension
Interventions
DRUG

Nebivolol 5 mg

1 tablet of study medication (5mg) to be administered orally according to instructions of Investigator.

DRUG

Ramipril 2.5/5/10 mg

1 tablet of study medication (2.5mg or 5mg or 10mg) to be administered orally according to instructions of Investigator.

Trial Locations (1)

7694

A & P Kft., Hosszúhetény

All Listed Sponsors
lead

Menarini International Operations Luxembourg SA

INDUSTRY

NCT06104423 - Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients | Biotech Hunter | Biotech Hunter